Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · IEX Real-Time Price · USD
8.69
+0.29 (3.39%)
Mar 28, 2024, 3:00 PM EDT - Market open
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
The company was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.
Country | United States |
Founded | 2014 |
IPO Date | May 18, 2016 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 61 |
CEO | Kevin P. Danahy |
Contact Details
Address: 3957 Point Eden Way Hayward, California 94545 United States | |
Phone | 510-906-4600 |
Website | pulsebiosciences.com |
Stock Details
Ticker Symbol | PLSE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001625101 |
CUSIP Number | 74587B101 |
ISIN Number | US74587B1017 |
Employer ID | 46-5696597 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Robert W. Duggan | Executive Chairman |
Kevin P. Danahy | President and Chief Executive Officer |
Darrin R. Uecker | Chief Technology Officer and Director |
Mitchell E. Levinson | Chief Strategy Officer |
Dr. Richard Nuccitelli Ph.D. | Chief Science Officer |
Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
Patty Perla | Vice President of Human Resources |
David Danitz | Senior Vice President of Engineering |
Dr. Gansevoort Dunnington M.D. | Chief Medical Officer |
Dr. Niv Ad M.D. | Chief Science Officer of Cardiac Surgery |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 11, 2024 | 8-K | Current Report |
Feb 14, 2024 | 8-K | Current Report |
Jan 9, 2024 | 8-K | Current Report |
Jan 2, 2024 | 8-K | Current Report |
Dec 22, 2023 | 8-K | Current Report |
Dec 20, 2023 | 8-K | Current Report |
Dec 15, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Dec 4, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 27, 2023 | DEF 14A | Other definitive proxy statements |
Nov 27, 2023 | 8-K | Current Report |